Maple Peak Investments Stock Quote MAP - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

0.02

Bid

0.005

Ask

0.04

Volume

0.00 Day's Range 0.00

0.01 52 Week Range 0.045

Market Cap

1.18M

Previous Close

0.02

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

27,939

Shares Outstanding

59,000,000

Dividend Yield

PE Ratio

-3.92

Earnings Per Share (EPS)

-0.01

Revenue

Net Profit

-298k

Sector

Finance Services

Industry

Unit Inv Tr, Closed-end Mgmt

Headquarters

Vancouver, British Columbia, Can

Founded

2016

Maple Peak Investments Inc is listed in the Finance Services sector of the TSX Venture Exchange with ticker MAP. The last closing price for Maple Peak Investments was $0.02. Over the last year, Maple Peak Investments shares have traded in a share price range of $ 0.01 to $ 0.045.

Maple Peak Investments currently has 59,000,000 shares outstanding. The market capitalization of Maple Peak Investments is $1.18 million. Maple Peak Investments has a price to earnings ratio (PE ratio) of -3.92.

豪マイクロバ、ソニック・ヘルスケアと初の販売代理店契約を締結

マイクロバとソニック・ヘルスケアが、オーストラリアでマイクロバの先進的な感染症検査技術MetaPanel™の販売に関する商業契約を締結この新しいメタゲノム診断検査は、病原微生物と遺伝子の包括的なパネルの...

Erste Vertriebsvereinbarung mit Sonic Healthcare abgeschlossen

Microba und Sonic Healthcare haben eine Geschäftsvereinbarung über die Lieferung der hochentwickelten Microba-Testtechnologie für Infektionskrankheiten MetaPanel™ nach Australien unterzeichnet...

Premier accord de distribution signé avec Sonic Healthcare

Microba et Sonic Healthcare ont maintenant signé un accord commercial pour fournir la technologie avancée de test des maladies infectieuses de Microba MetaPanel™ en Australie Ce nouveau test de...

First Distribution Agreement Executed with Sonic Healthcare

Microba and Sonic Healthcare have now signed a commercial agreement to deliver Microba’s advanced infectious disease testing technology MetaPanel™ into Australia This new metagenomic diagnostic...

マイクロバ、IBD治療薬の第I相臨床試験を開始

炎症性腸疾患におけるマイクロバの主要治療プログラムであるMAP 315の第I相臨床試験において、最初の被験者の投与が行われました。 MAP315は、潰瘍性大腸炎の治療薬として開発中の新規の生物学的製剤で、マイク...

Microba beginnt mit klinischer Phase-I-Studie zu Therapeutikum für chronisch-entzündliche Darmerkrankungen

Erste Teilnehmer erhielten erfolgreich das Prüfpräparat in einer klinischen Phase-I-Studie zu MAP 315, dem führenden Therapeutikum-Programm von Microba bei chronisch-entzündlichen...

Microba entame un essai clinique de phase I pour la thérapie des MII

Les premiers participants ont été dosés avec succès dans le cadre d’un essai clinique de phase I de MAP 315, le principal programme thérapeutique de Microba pour les maladies inflammatoires de...

Microba Commences Phase I Clinical Trial for IBD Therapeutic

First participants have been successfully dosed in a Phase I Clinical Trial of MAP 315, Microba’s lead Therapeutic Program in Inflammatory Bowel Disease. MAP 315, is a novel live biotherapeutic...